This is a translation of the original article in Portuguese. Read the original (Português).
New results from a phase 3 study show that Cagrisema, an obesity drug from the pharmaceutical company Novo Nordisk, led patients to lose an average of 21% of their body weight after 68 weeks, using reduced doses. The data were published by the Brazilian newspaper O Globo.
The company has already submitted its approval request to the U.S. regulatory agency. In Brazil, Anvisa (Brazil’s National Health Surveillance Agency) has no official plans yet to review the drug, which means there is no forecast for when it could reach Brazilian pharmacies.
At the same time, Novo Nordisk released results for an oral version of semaglutide, the active ingredient in the well-known obesity injection pens. Unlike Cagrisema, this pill version has already been approved by Anvisa and is expected to reach the Brazilian market next year.
Therefore, the outlook for Brazilian patients is split in two. On one side is Cagrisema, which showed striking results in a study but depends on approval in the United States and then on a review process that has not yet been announced in Brazil. On the other side is oral semaglutide, which has already cleared the regulatory stage in the country and now depends on arriving on pharmacy shelves.
Why the pill matters
For those following the topic, the oral version is the nearest new development. A pill tends to be simpler to use than an injection pen, and the expectation is that it could make treatment easier and eventually reduce costs. The price of the oral version in Brazil, however, has not yet been disclosed.
Obesity pens have become a health issue and also a budget issue for many Brazilians, since treatment is usually long-term and paid out of pocket. For that reason, the setting of prices and access options will be closely watched when the company details the launch.
Reporting from O Globo (p. 26, caderno nacional: "Cagrisema faz pacientes perderem 21% do peso em estudo").
Deixe um comentário